Mechanistically, these agents frequently downregulate E6/E7, restore p53/pRb signalling, trigger apoptosis and cell-cycle arrest, and may increase tumour immunogenicity—effects observed across in vitro and in vivo models [34,35,36,37,38,39,40,41,42,43]. This evidence concerns the gene TP53 and neoplasm.